MX2020008678A - Metodos de uso para derivados de benzotriazol trisustituidos. - Google Patents

Metodos de uso para derivados de benzotriazol trisustituidos.

Info

Publication number
MX2020008678A
MX2020008678A MX2020008678A MX2020008678A MX2020008678A MX 2020008678 A MX2020008678 A MX 2020008678A MX 2020008678 A MX2020008678 A MX 2020008678A MX 2020008678 A MX2020008678 A MX 2020008678A MX 2020008678 A MX2020008678 A MX 2020008678A
Authority
MX
Mexico
Prior art keywords
sub
methods
benzotriazole derivatives
trisubstituted benzotriazole
trisubstituted
Prior art date
Application number
MX2020008678A
Other languages
English (en)
Inventor
Sung Eun Choe
Danielle Ulanet
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2020008678A publication Critical patent/MX2020008678A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona métodos para tratar el cáncer en un sujeto con un derivado de benzotriazol trisustituido con la fórmula (I)(VER FORMULA) (I) o una sal farmacéuticamente aceptable de esta, en donde las variables R1, R2 y R3 son como se definen en la presente.
MX2020008678A 2018-02-20 2019-02-19 Metodos de uso para derivados de benzotriazol trisustituidos. MX2020008678A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2018018679 2018-02-20
PCT/US2019/018472 WO2019164794A1 (en) 2018-02-20 2019-02-19 Methods of use for trisubstituted benzotriazole derivatives

Publications (1)

Publication Number Publication Date
MX2020008678A true MX2020008678A (es) 2020-09-25

Family

ID=61692059

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008678A MX2020008678A (es) 2018-02-20 2019-02-19 Metodos de uso para derivados de benzotriazol trisustituidos.

Country Status (13)

Country Link
US (2) US11717512B2 (es)
EP (1) EP3755324B1 (es)
JP (2) JP7434185B2 (es)
KR (1) KR102861339B1 (es)
CN (1) CN111757731B (es)
AU (1) AU2019223906B2 (es)
BR (1) BR112020016929A8 (es)
CA (1) CA3091792A1 (es)
ES (1) ES3038736T3 (es)
MA (1) MA51897A (es)
MX (1) MX2020008678A (es)
TW (1) TWI818954B (es)
WO (1) WO2019164794A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL270066B2 (en) 2017-04-24 2023-10-01 Aurigene Oncology Ltd Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
KR102861339B1 (ko) * 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
CR20210394A (es) 2018-12-21 2021-12-13 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
CN111662872A (zh) * 2020-05-06 2020-09-15 西南医科大学附属医院 一种急性t淋巴细胞白血病阿糖胞苷耐药细胞株构建方法
EP4171552A1 (en) * 2020-06-24 2023-05-03 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
US20230285365A1 (en) * 2020-08-27 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10506632A (ja) 1995-05-10 1998-06-30 ファイザー・インコーポレーテッド 慢性関節リウマチを治療するためのメトトレキセートとテニダップとの組合せ物
EP1237546A2 (en) 1999-10-01 2002-09-11 Institute of Molecular and Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
US6841561B1 (en) 1999-10-01 2005-01-11 Institute Of Molecular And Cell Biology Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases
WO2003006424A1 (en) 2001-07-10 2003-01-23 4Sc Ag Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7652051B2 (en) * 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
SI1809622T1 (sl) 2004-09-22 2010-11-30 Janssen Pharmaceutica Nv Inhibitorji interakcije med MDM in P
JP2007015952A (ja) 2005-07-06 2007-01-25 Shionogi & Co Ltd ナフタレン誘導体
DE102005049953A1 (de) 2005-10-19 2007-04-26 Sanofi-Aventis Deutschland Gmbh Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen
BRPI0717035B8 (pt) 2006-09-08 2021-05-25 Hoffmann La Roche moduladores de benzotriazol cinase
WO2010081898A1 (en) 2009-01-19 2010-07-22 Neurosearch A/S Novel benzotriazole derivatives useful for the treatment of cns disorders
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
US9316632B2 (en) 2009-03-17 2016-04-19 Marshall University Research Corporation Methods of screening chemotherapeutic agents and treating cancer
SG174125A1 (en) 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
EP2509600B1 (en) 2009-12-09 2017-08-02 Agios Pharmaceuticals, Inc. Therapeutically active compounds for use in the treatment of cancer characterized as having an idh mutation
US20130109643A1 (en) 2010-05-10 2013-05-02 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
WO2013049112A1 (en) 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
CN103965133B (zh) 2013-01-31 2018-11-30 华东理工大学 一种具有dhodh抑制活性的含n、s杂环化合物及其制备和用途
HUE042032T2 (hu) 2013-02-25 2019-06-28 Aurigene Discovery Tech Ltd Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
JP6629840B2 (ja) 2014-05-08 2020-01-15 パノプテス・ファーマ・ゲーエムベーハー 眼の疾患および障害を処置するための化合物
EP3344243B1 (en) * 2015-09-01 2020-12-09 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
JP6961879B2 (ja) 2015-12-30 2021-11-05 レ ラボラトワール セルヴィエ ソシエテ・パール・アクシオンス・サンプリフィエ 変異体イソクエン酸デヒドロゲナーゼを包含する腫瘍の処置
JOP20190094A1 (ar) 2016-10-27 2019-04-25 Broad Inst Inc مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
US11311548B2 (en) 2017-03-02 2022-04-26 Aslan Pharmaceuticals Pte. Ltd. Cancer therapy
US20180369206A1 (en) 2017-04-24 2018-12-27 Aurigene Discovery Technologies Limited Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors
IL270066B2 (en) 2017-04-24 2023-10-01 Aurigene Oncology Ltd Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2019012030A1 (en) 2017-07-13 2019-01-17 INSERM (Institut National de la Santé et de la Recherche Médicale) DHODH INHIBITOR AND CHK1 INHIBITOR FOR THE TREATMENT OF CANCER
KR102861339B1 (ko) 2018-02-20 2025-09-19 르 라보레또레 쎄르비에르 삼치환 벤조트리아졸 유도체의 사용 방법
WO2020067412A1 (ja) 2018-09-28 2020-04-02 富士フイルム株式会社 シタラビンを含む抗腫瘍剤、シタラビンと併用される抗腫瘍効果増強剤、抗腫瘍用キット、およびシタラビンと併用される抗腫瘍剤
IL283503B2 (en) 2018-11-30 2025-10-01 Fond Centro San Raffaele Combination therapy for primary central nervous system lymphoma
CR20210394A (es) 2018-12-21 2021-12-13 Les Laboratoires Servier Sas Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéuticas del mismo
AU2020355125A1 (en) 2019-09-27 2022-04-14 The Rockefeller University Compositions and methods for treating metastatic gastrointestinal cancer
EP4171552A1 (en) 2020-06-24 2023-05-03 Les Laboratoires Servier Use of a dhodh inhibitor compound in combination cancer therapy
WO2021262874A1 (en) 2020-06-24 2021-12-30 Servier Pharmaceuticals , Llc Use of a dhodh inhibitor compound in combination cancer therapy
US20230285365A1 (en) 2020-08-27 2023-09-14 Servier Pharmaceuticals Llc Use of a dhodh inhibitor compound in combination cancer therapy

Also Published As

Publication number Publication date
CA3091792A1 (en) 2019-08-29
JP2023109974A (ja) 2023-08-08
CN111757731B (zh) 2024-06-25
EP3755324C0 (en) 2025-07-30
EP3755324B1 (en) 2025-07-30
TWI818954B (zh) 2023-10-21
KR20200123137A (ko) 2020-10-28
US11717512B2 (en) 2023-08-08
EP3755324A1 (en) 2020-12-30
US20210113531A1 (en) 2021-04-22
ES3038736T3 (en) 2025-10-14
MA51897A (fr) 2020-12-30
JP2021514395A (ja) 2021-06-10
WO2019164794A1 (en) 2019-08-29
AU2019223906B2 (en) 2024-11-21
BR112020016929A2 (pt) 2020-12-15
BR112020016929A8 (pt) 2022-06-28
AU2019223906A1 (en) 2020-09-10
US12290508B2 (en) 2025-05-06
TW201938543A (zh) 2019-10-01
US20240148697A1 (en) 2024-05-09
JP7434185B2 (ja) 2024-02-20
CN111757731A (zh) 2020-10-09
KR102861339B1 (ko) 2025-09-19

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
WO2017176957A8 (en) Mdm2 protein degraders
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
PH12020551464A1 (en) Cd73 inhibitors
MY196582A (en) PD-1/PD-L1 Inhibitors
EA202193015A1 (ru) Ингибиторы cdk
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
SG11201906579UA (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX392829B (es) Analogos sinteticos de las ecteinascidinas y su uso como agentes antitumorales
EA201992320A1 (ru) Пиперидины в качестве ковалентных ингибиторов менина
WO2018044767A3 (en) Aminopyrimidines as alk inhibitors
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
BR112020016929A8 (pt) Métodos de uso para derivados de benzotriazol trissubstituídos
MX393711B (es) Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres
PH12021552513A1 (en) Pyrrole compounds
MX394245B (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
SG11201907945YA (en) Azetidine derivative
EP4595969A8 (en) Compositions and methods for treatment of insulin resistance
WO2019195641A3 (en) 1,3,4-oxadiazoles as inhibitors of rho/mrtf/srf-mediated gene transcription and methods for use of the same
WO2019217933A8 (en) Inhibitors of the ras oncoprotein, methods of making and methods of use thereof

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: LES LABORATOIRES SERVIER